JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3012 Ruxolitinib (INCB018424)
4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A4135 Tofacitinib (CP-690550) Citrate
2 Citation

Target: JAK

Summary: Potent JAK inhibitor

≥25.22 mg/mL
A4136 TG101348 (SAR302503)
2 Citation

Target: FLT3|JAK|c-RET

Summary: JAK-2 inhibitor,potent and selective

≥26.23 mg/mL
A4138 Tofacitinib (CP-690550,Tasocitinib)
1 Citation

Target: JAK

Summary: Janus kinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥15.6 mg/mL
A4139 AG-490
3 Citation

Target: EGFR|JAK

Summary: JAK2/EGFR inhibitor

insoluble in H2O; ≥14.7 mg/mL
A4148 NVP-BSK805 2HCl

Target: JAK

Summary: JAK2 inhibitor

≥30.8 mg/mL
A4151 ZM 39923 HCl

Target: JAK

Summary: JAK3 inhibitor,potent and selective
A4152 BMS-911543

Target: JAK

Summary: JAK2 inhibitor,selective small molecule

≥43.3 mg/mL
A3937 XL019

Target: JAK

Summary: JAK2 inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥11.125 mg/mL
B1130 GLPG0634
1 Citation

Target: JAK

Summary: JAK1 inhibitor

≥21.3 mg/mL